Why go forth to SITC18 knowing its open label and mediocre data to report? Well O'connor and Bonstein team successfully campaigned and celebrated the two Keynote trials really well over the year. O'connor often over-mentioned at finance conferences how ONCS was the smallest Merck Keynote Partner, as if that was some weird advantage.... raised 45M in funds on the strength of these trials I guess that was their sole objective to poker face the truth until funding secured Too bad the data turned out so mixed. oh well that's biotech for you! Hopefully some good comes out of I/O combo therapy.. here with cytokines, STING as well, etc.. .we can all agree its been rather brutal since ESMO.
It will be hard for O'connor to shake his biotech CEO reputation tho
Don't for get to Vote folks!
News 
Market Data 
Discover 
